ライフサイエンスコーパス: subretinal fluid

1 istent fluid by fluid type (intraretinal and subretinal fluid).

2 teen tumors (86%) had complete resolution of subretinal fluid.

3 s (CRT) and the presence of intraretinal and subretinal fluid.

4 he optic disc pit and evaluate the source of subretinal fluid.

5 esis of cerebrospinal fluid as the source of subretinal fluid.

6 with the presence of previous or persistent subretinal fluid.

7 antly associated with previous or persistent subretinal fluid.

8 amcinolone acetonide, with resolution of the subretinal fluid.

9 etached than when only 1 quadrant (0.8%) had subretinal fluid.

10 were bilateral retinoblastoma and absence of subretinal fluid.

11 was there disturbance of the inner retina or subretinal fluid.

12 pigment) and free fluorophores within fresh subretinal fluid.

13 macular schisis, cystoid macular edema, and subretinal fluid.

14 f DME, central subfield thickness (CST), and subretinal fluid.

15 All 9 tumors were associated with shallow subretinal fluid.

16 3 months or until the complete resolution of subretinal fluid.

17 subretinal vacuum and facilitating increased subretinal fluid.

18 treoretinopathy, and delayed reabsorption of subretinal fluid.

19 nned outer nuclear layer and intraretinal or subretinal fluid.

20 ntified subretinal exudate, intraretinal and subretinal fluid.

21 tic choroidal lesion with associated shallow subretinal fluid.

22 ted for concomitant predominantly persistent subretinal fluid.

23 for the presence/absence of intraretinal and subretinal fluid.

24 T scans demonstrated bilateral resorption of subretinal fluid.

25 central acute middle maculopathy, and 1 with subretinal fluid.

26 be associated with persistent postoperative subretinal fluid.

27 o were reviewed qualitatively for persistent subretinal fluid.

28 re used to evaluate MEK inhibitor-associated subretinal fluid.

29 id macular edema (36% vs. 11.7%, p < 0.001), subretinal fluid (16.3% vs 6.4%, p = 0.04), and subfovea

30 ective material (24.0%; 95% CI, 0-45.2), and subretinal fluid (20.0%; 95% CI, 0-45.5).

31 ean CST, 370.5mum vs. 304.4mum; P = 0.0001), subretinal fluid (54.8% vs. 21.2%; P < 0.0001), and larg

32 On assessing OCT Biomarkers, Subretinal fluid (57.4%), Intraretinal Fluid (57.4%), ma

33 ess on B-scan ultrasonography (63% vs. 84%), subretinal fluid (58% vs. 90%), and orange pigment (50%

34 (8%, 20%, 38%, and 39%; P<0.001), associated subretinal fluid (64%, 80%, 82%, and 83%; P<0.001), intr

35 9), hyperreflective material and dots in the subretinal fluid (72.5% vs 34.5%, P < .001), internal li

36 rs; 60% were over 2 mm in thickness, 63% had subretinal fluid, 84% caused symptoms, 57% had orange pi

37 38%) configuration, and displayed associated subretinal fluid (85%).

38 TC group exhibited LBD > 5 mm (36% vs. 88%), subretinal fluid (9.1% vs. 56%), orange pigment (4.5% vs

39 choroid vessels underneath the retina cause subretinal fluid accumulation and retinal detachment.

40 in the PDT group had complete resolution of subretinal fluid accumulation compared to only 17% of pa

41 se that these changes may be attributable to subretinal fluid accumulation in our novel retinal detac

42 a vitrectomy alone with complete drainage of subretinal fluid achieves a high reattachment rate in th

43 , 2.4; CI, 1.7-3.6) versus </=75 mum, foveal subretinal fluid (aHR, 1.5; CI, 1.1-2.0) versus no subre

44 fluid alone, and 1 patient had peripapillary subretinal fluid alone.

45 spots located between a peripheral gutter of subretinal fluid and attached retina.

46 remain unclear, lead to the accumulation of subretinal fluid and autofluorescent waste products from

47 eral buckling to address perforation-related subretinal fluid and emphasize avoiding traction on the

48 D lens on slit lamp revealed the presence of subretinal fluid and few focal spots of retinal pigment

49 t reproducibility, particularly in eyes with subretinal fluid and greater choroidal thickness.

50 For all eyes with follow-up, the subretinal fluid and intraretinal edema were reversible

51 njection due to the presence of intraretinal/subretinal fluid and pigment epithelial detachment (PED)

52 he intense hyperfluorescence group with both subretinal fluid and posterior retinal cystoid degenerat

53 f the eyes had subretinal fluid only or both subretinal fluid and posterior retinal cystoid degenerat

54 The resolution of the subretinal fluid and recurrence rates were assessed in r

55 ing vitreous seed regression were absence of subretinal fluid and subretinal seeds.

56 solved after delivery with regression of the subretinal fluid and the disappearance of subfoveal exud

57 ness (CMT), and the presence of intraretinal/subretinal fluid and the height and presence of PED were

58 The presence of subretinal fluid and vitelliform material was noted in 7

59 Presence of subretinal fluid and vitelliform material were early fin

60 raster scans were evaluated for intraretinal/subretinal fluid and, when applicable, vitreomacular tra

61 s during buckling surgery (e.g., drainage of subretinal fluid) and concomitant diseases such as diabe

62 ad well-circumscribed vessels, 86% (6/7) had subretinal fluid, and 14% (1/7) had intraretinal fluid.

63 Poorly circumscribed vessels, subretinal fluid, and intraretinal fluid each were seen

64 of a retinal detachment by the injection of subretinal fluid, and intravitreal injection of green fl

65 rated less GA, less intraretinal fluid, more subretinal fluid, and less subretinal pigment epithelium

66 in odds of anti-VEGF treatment, presence of subretinal fluid, and macular hemorrhages in the post-lo

67 cysts, epiretinal membranes, microaneurysms, subretinal fluid, and outer layer disruption/reflectivit

68 , presence of macular edema, intraretinal or subretinal fluid, and pigment epithelial detachment were

69 with gradual resolution of intraretinal- and subretinal fluid, and remained stable in 12 months.

70 ponse depended on baseline BCVA, presence of subretinal fluid, and retinal angiomatous proliferation,

71 scan for the presence of intraretinal fluid, subretinal fluid, and sub-retinal pigment epithelium flu

72 inal fluid (aHR, 1.5; CI, 1.1-2.0) versus no subretinal fluid, and subretinal hyperreflective materia

73 hickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex), visual

74 Alterations of the OS overlying lesions with subretinal fluid are similar to those seen in central se

75 aseline OCT features (intraretinal cysts and subretinal fluid) are useful predictors of persistent di

76 condary changes (drusen, orange pigment, and subretinal fluid) associated with choroidal nevi in chil

77 out persistent fluid (cystic intraretinal or subretinal fluid at all 4 initial visits).

78 e (OR 2.95, 95% CI 1.67-5.20, p < 0.001) and subretinal fluid at baseline (OR 3.17, 95% CI 1.62-6.18,

79 In 11 of 19 patients with intraretinal or subretinal fluid at baseline judged to be reversible, si

80 erence tomography data, only the presence of subretinal fluid at baseline was associated with poorer

81 cular volume (> 9.99 mm(3)), and presence of subretinal fluid at baseline were all associated with ea

82 reater total macular volume, and presence of subretinal fluid at baseline were associated with more r

83 thickness (CMT), the number of patients with subretinal fluid at each follow-up time, the number of p

84 idence interval [CI], 0.19-0.80; P = 0.010), subretinal fluid at final visit (OR, 0.41; 95% CI, 0.25-

85 Less than 6% of eyes had subretinal fluid at month 60.

86 with intermediate hyperfluorescence had only subretinal fluid at OCT and a dry macula was obtained in

87 nal fluid (AUC: 0.81; 95% CI: 0.81-0.86) and subretinal fluid (AUC 0.88; 95% CI: 0.85-0.91).

88 for creation of a permanent intraretinal and subretinal fluid barrier.

89 e pigmented epithelial detachments, SMH, and subretinal fluid before and after SMH.

90 a shallow decline in acuity with increasing subretinal fluid but a much steeper decline with equival

91 escence from lipofuscin within RPE and fresh subretinal fluid, but when choroidal haemangioma is chro

92 Group 2 comprised 7 eyes without subretinal fluid, but with intraretinal fluid.

93 total of 71 eyes with "resolved" (absence of subretinal fluid) chronic CSC at baseline and 36 months

94 s causes of retinal fluid, but was worst for subretinal fluid compared to intraretinal or sub-retinal

95 b-treated eyes had resolved intraretinal and subretinal fluid compared with aflibercept-treated eyes.

96 Due to signs of growth and subretinal fluid detected on OCT, malignancy was suspect

97 /= 20/40) except in a single patient in whom subretinal fluid developed under the fovea.

98 tures (size, location, color, shape, related subretinal fluid) did not impact tumor control.

99 nderwent 23-gauge pars plana vitrectomy with subretinal fluid drainage through PRB (n = 100), PR (n =

100 ous, rather than intermittent, monitoring of subretinal fluid drainage via indirect ophthalmoscopy.

101 d to the area with neovascularization and no subretinal fluid drainage was performed.

102 f RRD, area of RRD, foveal status, method of subretinal fluid drainage, retinal pigment epithelium (R

103 External drainage of subretinal fluid during scleral buckling procedures is c

104 half-dose group had at least 1 recurrence of subretinal fluid during the follow-up.

105 vidualized follow-up and further research on subretinal fluid dynamics are needed to optimize treatme

106 reated patients demonstrated a resolution of subretinal fluid (evaluation visit 1: 57% in the PDT gro

107 HSML-treated patients showed a resolution of subretinal fluid (evaluation visit: 1:48% in the PDT gro

108 retinal detachment from 11 to 3 o'clock with subretinal fluid extending into the macula.

109 The subretinal fluid foci associated with MEK inhibitors hav

110 All subretinal fluid foci occurred between the interdigitati

111 FGFR inhibitors result in subretinal fluid foci similar to other drugs that inhibi

112 hibit recurrent or resistant intraretinal or subretinal fluid following multiple injections with eith

113 han 3 mm in size, macular location, or minor subretinal fluid; group C = retinoblastoma with localize

114 Infants with bilateral subretinal fluid had an older gestational age compared w

115 The mean maximum subretinal fluid height decreased from 126.6 mum at enro

116 Central subfield thickness, maximum subretinal fluid height, and maximum pigment epithelial

117 Changes in maximum subretinal fluid height, maximum pigment epithelial deta

118 age, larger tumor, and greater incidence of subretinal fluid, hemorrhage, and extraocular extension.

119 the eye (fundus) is a critical regulator of subretinal fluid homeostasis, which determines the overa

120 iretinal membrane presence, intraretinal and subretinal fluid, hyperreflective foci, disorganization

121 n for the presence of perforation-associated subretinal fluid in 4/7 eyes.

122 caused by bilateral patching on the flow of subretinal fluid in a physical model of retinal detachme

123 Optical Coherence Tomography revealed serous subretinal fluid in both eyes.

124 ol may reduce central subfield thickness and subretinal fluid in eyes with persistent exudation despi

125 ual acuity and may demonstrate resolution of subretinal fluid in the absence of surgical intervention

126 On subsequent visit 7 months later, subretinal fluid in the location of the capillary macroa

127 , controversy exists regarding the source of subretinal fluid in these cases.

128 asing subretinal hyperreflective material or subretinal fluid in this circumstance reduces vision fur

129 s without fluid (absence of intraretinal and subretinal fluid) in the central subfield at week 16 and

130 3 %) pigment epithelial detachment, 6 (55 %) subretinal fluid, in 29 (39 %) eyes regardless of the le

131 sistant to treatments aimed at resolving the subretinal fluid, including some combination of anti-vas

132 The percentage of patient visits with no subretinal fluid increased from 0.5% to 41% after the in

133 hs after oral treatment with eplerenone, the subretinal fluid increased significantly.

134 s plana vitrectomy, external drainage of the subretinal fluid, intraoperative systemic hypertension,

135 coherence tomography (OCT) features such as subretinal fluid, intraretinal cysts and intraretinal fl

136 g at the time of eAMD diagnosis demonstrated subretinal fluid, intraretinal cysts, or both consistent

137 dence of CNV activity on SD OCT (presence of subretinal fluid, intraretinal fluid, and/or cystoid spa

138 (M24) for central subfield thickness (CST), subretinal fluid, intraretinal fluid, vitreoretinal inte

139 ated with signs of active myopic CNV (either subretinal fluid/intraretinal cysts on SD OCT or dye lea

140 Persistent subretinal fluid is associated with increased subfoveal

141 depigmentation area, subretinal haemorrhage, subretinal fluid, macula thickness, macular scar, subret

142 estational age compared with infants without subretinal fluid (median, 40.4 vs 39.1 weeks, respective

143 ovement >=15 letters; and extensive baseline subretinal fluid modestly predicted CST <=250 mum (OR, 1

144 Associated findings included subretinal fluid (n = 14/17 [82%]) and macular edema (n

145 orrhage (n = 2), retinal hemorrhage (n = 4), subretinal fluid (n = 4), and/or intraretinal exudation

146 OCT characteristics included subretinal fluid (n = 5), intraretinal fluid and cysts (

147 pigment epithelial alterations (n = 9; 53%), subretinal fluid (n = 5; 29%), and orange pigment (n = 3

148 Associated features included subretinal fluid (n = 6), subretinal exudation (n = 6),

149 Related features included subretinal fluid (n = 9; 19%), cystoid retinal edema (n

150 The presence of subretinal fluid (odds ratio [OR], 1.98; 95% confidence

151 We evaluated VEGF and HGF protein levels in subretinal fluid of eyes with ROP, and expression of the

152 All 15 eyes (100%) showed subretinal fluid on iOCT.

153 n in the macula (57.4% vs. 67.5%, P = 0.01), subretinal fluid on OCT (33.3% vs. 70.7%, P = 0.01), and

154 rs (68.5% vs. 55.3%; P = 0.003), and to have subretinal fluid on OCT (86.7% vs. 81.0%; P = 0.047).

155 Median time to complete resolution of subretinal fluid on OCT was 3.7 weeks (range, 2-12 weeks

156 retinal thickening with shadowing and intra-/subretinal fluid on OCT, hypoautofluorescence on fundus

157 al foveal thickness (CFT), and resolution of subretinal fluid on optical coherence tomography at 1 an

158 dilated retinal examination, 1 of which had subretinal fluid on SD OCT.

159 undus was stopped and a disappearance of the subretinal fluid on SD-OCT was observed.

160 cence group, 82.6% and 17.4% of the eyes had subretinal fluid only or both subretinal fluid and poste

161 In the intense hyperfluorescence group with subretinal fluid only, a dry macula was obtained in 89.5

162 gion, as epiretinal membrane, macular edema, subretinal fluid or alterations of the outer layers of t

163 follow-up and/or persistent intraretinal or subretinal fluid or detectable choroidal neovascularisat

164 anism of action does not require drainage of subretinal fluid or intraocular gas tamponade.

165 indication was recurrence of intraretinal or subretinal fluid or new hemorrhage.

166 reatment criteria relying on intraretinal or subretinal fluid or new hemorrhages may be expanded to i

167 , and hyporeflectivity changes due to either subretinal fluid or pigment epithelial detachments.

168 tion of fluid in the neuroepithelium, namely subretinal fluid or posterior retinal cystoid degenerati

169 rrhage (OR, 1.44; 95% CI, 1.04-2.00), and no subretinal fluid (OR, 2.15; 95% CI, 1.06-4.40) predicted

170 atures of basal diameter > 5 mm, presence of subretinal fluid, or thickness too large for capture by

171 ly associated with presence of non-exudative subretinal fluid (P < .001), non-exudative subretinal hy

172 y (BCVA) at baseline (P = .001), presence of subretinal fluid (P = .001), and retinal angiomatous pro

173 dal vessels, correlated with the presence of subretinal fluid (P = .008) and reducing in caliber afte

174 mor thickness (P = .001) and the presence of subretinal fluid (P = .05), and the only factor predicti

175 increasing tumor thickness (P = 0.010), and subretinal fluid (P = 0.001).

176 = 0.005), -0.200 (-1.20, 0.60) in cases with subretinal fluid (p = 0.207), 0.000 (-0.60, 0.30) in pig

177 ween the tumor and the optic disc (P=0.026), subretinal fluid (P=0.035), thickness of residual tumor

178 ment, and 1 eye (12.5%) had minimal residual subretinal fluid parafoveally.

179 al RPE accumulation of lipofuscin as well as subretinal fluid, particularly on the fresh advancing tu

180 In another two eyes, minimal subretinal fluid persisted despite hole closure.

181 Intraoperative subretinal fluid persists under PFO tamponade with high

182 aled bilateral hypertensive retinopathy with subretinal fluid, pigment epithelial detachments, and re

183 iagnosis of PSF was made by the detection of subretinal fluid pockets on OCT beyond 6 weeks after sur

184 kness more than 2 mm, presence of associated subretinal fluid, presence of orange pigment on the tumo

185 not at 0.15 mM, also significantly enhanced subretinal fluid reabsorption (P < 0.05).

186 the development of INS37217 for stimulating subretinal fluid reabsorption in conditions that result

187 e results demonstrate that INS37217 enhances subretinal fluid reabsorption in experimental retinal de

188 In vivo INS37217 enhances the rates of subretinal fluid reabsorption in experimentally induced

189 tion of 1 mM INS37217 significantly enhanced subretinal fluid reabsorption when compared with vehicle

190 (30%), related to subfoveal scar, persistent subretinal fluid, reactive exudation, radiation maculopa

191 No subretinal fluid recurrence was observed during the 12-m

192 The mean time of the subretinal fluid resolution was significantly shorter in

193 t observed in the contralateral eye or after subretinal fluid resolution.

194 Subretinal fluid resolved in 13/18 eyes (72 %), and subr

195 Subretinal fluid resolved in 70% of pooled aflibercept-t

196 Subretinal fluid resolved in 81% by the last post-PDT vi

197 For 26 eyes (65%) with follow-up, the subretinal fluid resolved without medical intervention o

198 s mnemonic represent T (Thickness >2 mm), F (subretinal Fluid), S (Symptoms), O (Orange pigment), and

199 We examined subretinal fluid samples from eyes using rhegmatogenous

200 simultaneous measurement of 50 biomarkers in subretinal fluid samples obtained from patients who unde

201 acteristics and variations in a patient with subretinal fluid secondary to a carotid cavernous fistul

202 eline central subfield cystoid spaces and/or subretinal fluid showed more improvement (13.7 or 17.2 l

203 nt association was found between presence of subretinal fluid (SRF) (P = 0.0318) and vision loss >=5

204 nt association was found between presence of subretinal fluid (SRF) (P = 0.0318) and vision loss 5 le

205 ee eyes with a closed hole showed persistent subretinal fluid (SRF) after gas absorption.

206 raphy scan evaluation showed the presence of subretinal fluid (SRF) and pachychoroid supporting the d

207 Subretinal fluid (SRF) and vitreous from patients with r

208 s were defined, such as the baseline area of subretinal fluid (SRF) as measured on ultrasound images

209 al retinal thickness (CRT) and resolution of subretinal fluid (SRF) at baseline as well as 1, 3, 6 an

210 early residual intraretinal fluid (IRF) and subretinal fluid (SRF) at week 12.

211 orrected visual acuity (BCVA), resolution of subretinal fluid (SRF) demonstrated by optical coherence

212 e features in 24 of 30 eyes (80%), including subretinal fluid (SRF) in 20 of 30 eyes (67%) and retina

213 (CSC) is characterized by an accumulation of subretinal fluid (SRF) in the macula.

214 Hyper-AF corresponded to areas of subretinal fluid (SRF) on spectral-domain OCT and was fo

215 female sex (OR=5.7, p=0.008) and presence of subretinal fluid (SRF) only (OR=8.0, p=0.005) were indep

216 ical characteristics, presence of persistent subretinal fluid (SRF) or intraretinal fluid (IRF), and

217 On OCT, subretinal fluid (SRF) was detected in 77% of CM patient

218 uantify intraretinal cystoid fluid (IRC) and subretinal fluid (SRF) was developed.

219 At baseline, subretinal fluid (SRF) was present in 57% of patients wi

220 ial lesion complex was present in 86.4%, and subretinal fluid (SRF) was present in 76.3%.

221 patient, and patients who still demonstrated subretinal fluid (SRF) were included in the current stud

222 acute CSCR led to a significant decrease in subretinal fluid (SRF) with 95% of treated patients havi

223 f eyes had intraretinal fluid (IRF), 38% had subretinal fluid (SRF), 36% had subretinal pigment epith

224 resence of intraretinal cystoid fluid (IRC), subretinal fluid (SRF), and pigment epithelial detachmen

225 ed OCT, including intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachmen

226 changes, such as intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachmen

227 s (nanoliters) for intraretinal fluid (IRF), subretinal fluid (SRF), and pigment epithelial detachmen

228 e BCVA and higher CST, EZ total attenuation, subretinal fluid (SRF), and SHRM volume at baseline than

229 ns for presence of intraretinal fluid (IRF), subretinal fluid (SRF), and sub-retinal pigment epitheli

230 l center point and intraretinal fluid (IRF), subretinal fluid (SRF), and subretinal pigment epitheliu

231 presence of intraretinal fluid (IRF) and/or subretinal fluid (SRF), and subretinal pigment epitheliu

232 tina, pigment epithelial detachments (PEDs), subretinal fluid (SRF), and subretinal tissue (SRT).

233 gorithm quantified intraretinal fluid (IRF), subretinal fluid (SRF), and total retinal fluid from OCT

234 wth of RPE/drusenoid material and persistent subretinal fluid (SRF), but also a RPE-independent visua

235 Data collected included presence of subretinal fluid (SRF), macular edema or intraretinal ed

236 ed visits where cystoid macular edema (CME), subretinal fluid (SRF), or pigment epithelial detachment

237 s included intraretinal cystoid fluid (IRC), subretinal fluid (SRF), pigment epithelial detachment, a

238 eat maps of cystic intraretinal fluid (IRF), subretinal fluid (SRF), pigment epithelial detachments (

239 At 2 years, intraretinal fluid (IRF), subretinal fluid (SRF), sub-retinal pigment epithelium (

240 ina (NSR), drusen, intraretinal fluid (IRF), subretinal fluid (SRF), subretinal hyperreflective mater

241 Intraretinal fluid (IRF), subretinal fluid (SRF), subretinal pigment epithelium fl

242 Changes in thickness/volume of the retina, subretinal fluid (SRF), subretinal tissue (SRT), and pig

243 ume were calculated for neurosensory retina, subretinal fluid (SRF), subretinal tissue, and pigment e

244 smaller area of occult CNV, and presence of subretinal fluid (SRF).

245 ocation, and amount of intraretinal fluid or subretinal fluid (SRF); (4) presence, location, and amou

246 case series, % in literature, respectively): subretinal fluid (SRF; 30,9), chorioretinal folds (30,68

247 nt of exudation (P = 0.004), and presence of subretinal fluid (SRF; P = 0.004).

248 hickness [CST], intraretinal fluid [IRF], or subretinal fluid [SRF]) versus aflibercept (q8-week).

249 disease activity (intraretinal cysts [IRC], subretinal fluid [SRF], diffuse retinal edema [DRE], ret

250 ps: anti-VEGF-resistant eyes with persistent subretinal fluid, subretinal hemorrhage, or macular edem

251 e impact on acuity of defined OCT changes in subretinal fluid, subretinal hyperreflective material, a

252 boundaries included the neurosensory retina, subretinal fluid, subretinal tissue, and pigment epithel

253 ineated by these boundaries included retina, subretinal fluid, subretinal tissue, and pigment epithel

254 n size on OCT and exam and resolution of the subretinal fluid suggesting that the lesion had become i

255 uced visual acuity (VA) with the presence of subretinal fluid temporal to the disc extending to the f

256 of the left eye showed a geographic patch of subretinal fluid temporal to the macula that was associa

257 BRO6 subjects had intraretinal fluid and/or subretinal fluid than AFL subjects.

258 hree-month follow-up, SD-OCT revealed subtle subretinal fluid that resolved spontaneously over time.

259 linically relevant disease features, such as subretinal fluid, that were missed by FP, and had a lowe

260 For detecting subretinal fluid, the investigator metrics were 0.946 (9

261 ributions that reflect the path of spread of subretinal fluid, their position can be used to localize

262 .49; 95% CI, 0.29-0.82), OCT measurements of subretinal fluid thickness of >25 mu (aHR, 0.52; 95% CI,

263 hain proteins were detected in the collected subretinal fluid through electrophoresis in one eye.

264 Matrix metallopeptidase-1 correlated with subretinal fluid volume (r = 0.50; P = .01).

265 on about CNV, CNV volume, retinal thickness, subretinal fluid volume and height of neurosensory detac

266 Subretinal fluid volume on iOCT imaging was quantified.

267 sis of clinically relevant features, such as subretinal fluid volume or pigment epithelial detachment

268 th visual acuity outcome, and intraoperative subretinal fluid volume under PFO tamponade also may be

269 Increased intraoperative subretinal fluid volume under PFO tamponade trended towa

270 uced by >65% (P < 0.001) and central macular subretinal fluid volume was reduced by >99% in both arms

271 SD +/- 15.4) in which complete resolution of subretinal fluid was achieved after subthreshold micropu

272 At 12 months, a complete resolution of subretinal fluid was achieved in 26 half-fluence-treated

273 ter PDT, complete control with resolution of subretinal fluid was achieved in 7 tumors (78%), with me

274 Partial or complete resolution of subretinal fluid was achieved in 93% of patients.

275 Subretinal fluid was associated with better VA.

276 successfully re-attached surgically and the subretinal fluid was gradually absorbed within three mon

277 Overlying subretinal fluid was identified by EDI OCT (16%), ophtha

278 For participants in whom subretinal fluid was identified on standard OCT (Carl Ze

279 Subretinal fluid was noted on follow-up examination to h

280 At 1 month a complete resolution of subretinal fluid was observed in 19 half-fluence-treated

281 vitreal bevacizumab until no intraretinal or subretinal fluid was observed on optical coherence tomog

282 revealed a thicker choroidal thickness when subretinal fluid was present as compared to that observe

283 Subretinal fluid was present in 71% of patients, and PVD

284 Subretinal fluid was present in all the predominantly cl

285 ndently and diagnosed DME if intraretinal or subretinal fluid was present.

286 At M01, subretinal fluid was seen in 28.5% intraretinal fluid in

287 almost four months a total resolution of the subretinal fluid was visualized in both eyes without the

288 er subretinal tissue complex and presence of subretinal fluid were associated with less GA developmen

289 However, changes in intraretinal and subretinal fluid were not significant.

290 T), as well as associated features including subretinal fluid, were recorded before PDT and during fo

291 normalizes faster after surgery in eyes with subretinal fluid when compared with eyes with intraretin

292 t or multiple recurrences of intraretinal or subretinal fluid while receiving monthly bevacizumab or

293 EDI-OCT disclosed macular subretinal fluid with an increase of choroidal thickness

294 y (BCVA) 20/40 or worse, and intraretinal or subretinal fluid with central foveal thickness (CFT) equ

295 On SS OCT, we observed subretinal fluid with elevation of the fovea (group 1) i

296 al thinning overlying choroidal nevus; fresh subretinal fluid with preservation of photoreceptors ove

297 detachment (PED) in right eye and a cuff of subretinal fluid with underlying yellow deposits along s

298 underwent PPV alone and complete drainage of subretinal fluid, with air, 20% sulfur hexafluoride (SF6

299 Inclusion criterion was a lack of subretinal fluid within the whole area of the central re

300 In patients with persistent intraretinal or subretinal fluid, ziv- aflibercept 1.25 mg (0.05 ml) was